CAR T cells may be a particularly attractive option in ACC given the high level of chemoresistance; however, CAR T cells generally have more toxicity than ADCs43 and thus it may advisable to accrue safety information on targeting DLK1 from our phase 1 study before pursuing clinical testing of CAR T cells. The gene discussed is DLK1; the disease is adrenal cortex carcinoma.